The United Kingdom and the United States have signed a landmark bilateral deal that will guarantee zero import taxes on UK drug shipments being sold in the US market.
The Terms of the Pact
As part of the deal, the UK has agreed to increase spending on pharmaceuticals through the public health system. This move secures that import taxes on these key exports will stay at nothing for a duration of the next three years.
This deal is in response to previous statements to dramatically increase import taxes on branded pharmaceutical products, with increases discussed reaching one hundred percent.
"This arrangement between the UK bolsters the global environment for innovative medicines and introduces long-overdue fairness to transatlantic drug exports," a release said.
Commercial Significance
Medicines represent one of the UK's biggest export categories to the America, which is easily the biggest destination for leading companies like GSK and AstraZeneca.
Statistics reveal that in the 12 months to the end of last September, the UK sold drugs worth £11.1bn to the US. This value accounted for 17.4% of all goods exports in that timeframe.
"This deal secures employment, stimulates capital expenditure and facilitates the UK to emerge as a international leader for life sciences," a government official commented.
Specific UK Commitments
The pact includes several notable changes from the British government:
- Revised Affordability Limit: The UK will increase the price threshold at which it judges new medicines to be too expensive by 25%.
- Boosted Medicine Funding: There is a aim to increase total NHS spending on drugs from 0.3% of the national economy to 0.6 percent over the following ten-year period.
- Rebate Cap: The sum pharmaceutical firms must refund to the NHS to stay within budget will be capped at fifteen percent. In the past, repayments topped twenty percent.
Industry Background
The pact takes place against a protracted dispute between the sector and the UK government over medicine costs and NHS adoption.
These tensions were heightened by claims that American customers were charged a premium for the identical medicines than consumers in the Britain and the EU.
Over the last 18 months, several large manufacturing plans in the UK have been paused or abandoned, while multi-billion-dollar expansions have been directed toward US facilities.
A senior figure publicly accepted that the NHS needed to spend more on medicines, noting that its budget allocation on drugs had declined as a proportion of its resources over the previous ten-year period.
